IPO Advisory
In-depth, experienced and seamless execution throughout the IPO Process.
IPO Detail
IPO Information
Financial
Financial Report
Peer Comparison
Peer Comparison Report
Performance
Performance Report
Indo US Bio-Tech IPO is a Fixed Price listing on BSE SME exchange, with an ipo size of ₹ 7.29 Cr. The company is based in Ahmedabad and caters to Agro - Food Products sector. Swastika Investmart is the merchant banker of Indo US Bio-Tech IPO. It is a SME IPO which filed its Draft Red Herring Prospectus (DRHP) on 5th March 2018.
Indo US Bio-Tech IPO posted revenues of ₹ 27.15 crores and PAT of ₹ 1.27 crores in FY18 on annualised basis.
Revenue:
₹ 27.15 Cr.
EBITDA Margin:
97.22
% 
Net Worth: ₹ 4.62 Cr.
Market Capitalisation:
[●]
P/E:
19.00 times
P/BV: [●]
EV/EBITDA: [●]
Financial results of Indo US Bio-Tech IPO based on restated financials as per prospectus and IPO review parameters can be referred to below.
| Financials | Oct-17 | FY17 | FY16 | FY15 | |
|---|---|---|---|---|---|
|
Balance Sheet
|
|||||
| Assets | 20.55 | 12.93 | 13.68 | 7.67 | |
| Net Worth | 4.62 | 3.88 | 3.24 | 2.89 | |
| Total Debt | 6.37 | 4.84 | 4.66 | 1.66 | |
|
Profit & Loss
|
|||||
Revenue
Revenue on annualised basis |
15.84
27.15 |
24.53 | 19.04 | 19.57 | |
EBITDA
EBITDA on annualised basis |
15.40
26.40 |
24.24 | 19.25 | 19.83 | |
PAT
PAT on annualised basis |
0.74
1.27 |
0.64 | 0.35 | 0.49 | |
Indo US Bio-Tech IPO PAT Margin is 4.67 % , ROCE (Return on Capital Employed) is [●] % as per latest financial. The below table shows Indo US Bio-Tech IPO Key Performance Indicators (KPI) as mentioned in company’s prospectus.
| Particulars | Oct-17 | FY17 | FY16 | FY15 |
|---|---|---|---|---|
| EBITDA Margin (%) | 97.22 | 98.82 | 101.10 | 101.33 |
| PAT Margin (%) | 4.67 | 2.61 | 1.84 | 2.50 |
| EPS (₹) | 5.00 | 4.37 | 2.42 | 4.17 |
| ROE (%) | 16.02 | 16.49 | 10.80 | 16.96 |
| ROCE (%) | [●] | [●] | [●] | [●] |
| ROA (%) | 3.60 | 4.95 | 2.56 | 6.39 |
| Debt to Equity | 1.38 | 1.25 | 1.44 | 0.57 |
The market Capitalisation of Indo US Bio-Tech IPO is ₹ [●] crores at the time of IPO and other IPO valuation metrics of this IPO is mentioned below.
The Indo US Bio-Tech IPO prospectus highlights an Return on Equity (ROE) of 16.02 % , Return on Assets (ROA) of 3.60 %, and an EBITDA Margin of 97.22 %, showcasing financial performance.
Profitability ratios like Return on Equity (ROE), Return on Assets (ROA), and Net Profit Margin shows Indo US Bio-Tech IPO financial report. Analysing these metrics can provide insights into the company’s efficiency, profitability, and long-term growth potential.
The post-IPO market capitalisation of Indo US Bio-Tech IPO is ₹ [●] Cr., based on the issue price and share structure. It helps investors gauge the company’s valuation and compare it with industry peers before investing.
The Indo US Bio-Tech IPO has a Price-to-Earnings (PE) ratio of 19.00 X, indicating valuation compared to industry peers. It helps investors determine if the stock is overvalued or undervalued compared to its earnings and industry peers.
Indo US Bio-Tech IPO reported revenue of ₹ 27.15 Cr. in the latest fiscal year, showing business performance, on annualised basis. Revenue figures from Indo US Bio-Tech IPO provide insights into sales growth, market demand, and business scalability.
Indo US Bio-Tech recorded an EBITDA of ₹ 26.40 Cr., reflecting operational efficiency. EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortisation) measures operational profitability.
Indo US Bio-Tech Profit After Tax (PAT) is ₹ 1.27 Cr., reflecting earnings growth. Profit After Tax (PAT) reflects the company’s actual earnings after all expenses, taxes, and deductions
Revenue:
₹ 27.15 Cr.
EBITDA Margin:
97.22
%
Net Worth: ₹ 4.62 Cr.
Market Capitalisation:
[●]
P/E:
19.00 times
P/BV: [●]
EV/EBITDA: [●]
Indo US Bio-Tech operates in Agro - Food Products and Business Of Breeding Products. The Issue is listed on BSE SME in May, 2018. Indo US Bio-Tech IPO size was 7.29 with Issue price of 51.00 .
Merchant Banker(s) of Indo US Bio-Tech IPO: Swastika Investmart Limited
Indo US Bio-Tech IPO subscription was 19.74 X. IPO subscription refers to applications received in an IPO by each quota, i.e., QIB, Retail, and NII. In some IPOs, Eligible employee quota and shareholder’s quota are also present. Learn more about IPO subscriptions here.
Indo US Bio-Tech IPO listed at a listing price of 57.80 against the offer price of 51.00.
The current market price of Indo US Bio-Tech is 154.63.
Why Us?
